期刊
BLOOD
卷 105, 期 9, 页码 3458-3464出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-07-2908
关键词
-
类别
资金
- NCRR NIH HHS [RR-02512] Funding Source: Medline
- NHLBI NIH HHS [P01 HL064190, P01-HL64190, R24 HL063098] Funding Source: Medline
- PHS HHS [K01-060 580] Funding Source: Medline
In earlier work, we showed that adeno-associated virus-mediated delivery of a Factor IX gene to skeletal muscle by direct intramuscular injection resulted in therapeutic levels of circulating Factor IX in mice. However, achievement of target doses in humans proved impractical because of the large number of injections required. We used a novel intravascular delivery technique to achieve successful transduction of extensive areas of skeletal muscle in a large animal with hemophilia. We provide here the first report of long-term (> 3 years, with observation ongoing), robust Factor IX expression (circulating levels of 4%-14%) by muscle-directed gene transfer in a large animal, resulting in essentially complete correction of the bleeding disorder in hemophilic dogs. The results of this translational study establish an experimental basis for clinical studies of this delivery method in humans with hemophilia B. These findings also have immediate relevance for gene transfer in patients with muscular dystrophy. (c) 2005 by The American Society of Hematology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据